News coverage about ACADIA Pharmaceuticals (NASDAQ:ACAD) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ACADIA Pharmaceuticals earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.0341317405821 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the news stories that may have effected Accern Sentiment’s analysis:
- ACADIA Pharmaceuticals Inc. (ACAD) Stock Recap – Wall Street Morning (wallstreetmorning.com)
- BidaskClub Upgrades ACADIA Pharmaceuticals (ACAD) to Hold (americanbankingnews.com)
- Investors Focused Stock: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Market Breaking Point (press release) (journalfinance.net)
- ACADIA Pharmaceuticals Inc., (NASDAQ: ACAD) – Hot Stock That Must Be in Your Portfolio – Stock Watch (stocksnewstimes.com)
- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Is the Stock Overvalued? – Nasdaq Journal (press release) (nasdaqjournal.com)
ACADIA Pharmaceuticals (ACAD) traded down $1.07 on Friday, reaching $30.11. 846,800 shares of the company’s stock traded hands, compared to its average volume of 1,330,000. The stock has a market capitalization of $3,820.00, a P/E ratio of -12.24 and a beta of 3.80. ACADIA Pharmaceuticals has a fifty-two week low of $25.06 and a fifty-two week high of $41.20.
A number of analysts recently issued reports on ACAD shares. Ladenburg Thalmann Financial Services reissued a “buy” rating and set a $50.00 price target (up from $48.00) on shares of ACADIA Pharmaceuticals in a report on Monday, October 2nd. Goldman Sachs Group reissued a “neutral” rating and set a $45.00 price target on shares of ACADIA Pharmaceuticals in a report on Friday, October 6th. Leerink Swann reissued a “market perform” rating on shares of ACADIA Pharmaceuticals in a report on Monday, October 9th. Needham & Company LLC reissued a “buy” rating and set a $49.00 price target on shares of ACADIA Pharmaceuticals in a report on Sunday, September 17th. Finally, Bank of America increased their price target on shares of ACADIA Pharmaceuticals from $40.00 to $46.00 and gave the stock a “positive” rating in a report on Thursday, October 5th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $48.86.
In other ACADIA Pharmaceuticals news, EVP Glenn Baity sold 37,500 shares of the stock in a transaction on Thursday, October 5th. The shares were sold at an average price of $40.91, for a total transaction of $1,534,125.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 22.25% of the company’s stock.
About ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).
Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.